Atlas Trials

LIB Therapeutics LLC

12 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch LIB Therapeutics LLC

RecordFirmDate
Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH (NCT07102511)LIB Therapeutics LLC2026-07-20
Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients (NCT05004675)LIB Therapeutics LLC2022-06-20
Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product (NCT05234775)LIB Therapeutics LLC2022-01-28
Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction (NCT04797247)LIB Therapeutics LLC2021-04-22
Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction (NCT04797104)LIB Therapeutics LLC2021-04-22
Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction (NCT04806893)LIB Therapeutics LLC2021-04-22
Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients (NCT04790513)LIB Therapeutics LLC2021-04-22
Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction (NCT04798430)LIB Therapeutics LLC2020-12-03
Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH (NCT04034485)LIB Therapeutics LLC2019-12-07
Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003 (NCT03847974)LIB Therapeutics LLC2019-02-14
Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction (NCT03549260)LIB Therapeutics LLC2018-05-22
Study to Evaluate the Safety, PK, and Pharmacodynamics of LIB003 (NCT03545438)LIB Therapeutics LLC2017-10-30

Track LIB Therapeutics LLC automatically

Every clearance here is in the API, with alerts when new ones post.